Orforglipron: all 52 studies that test it

Page 1 of 1. Open to participants first (11), then studies with results posted, then the rest; newest registration first within each.

• A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityRecruitingNCT07794579Phase 3
• A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health ProblemsNot yet recruitingNCT07790861Phase 3
• PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic ResponsesNot yet recruitingNCT07739537Phase 4
• Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy DiscontinuationNot yet recruitingNCT07729332Phase 4
• A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesRecruitingNCT07668336Phase 3
• A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan FastingRecruitingNCT07613307Phase 3
• A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)RecruitingNCT07241390Phase 3
• Efficacy and Safety of Orforglipron in Participants With Peripheral Artery DiseaseRecruitingNCT07223593Phase 3
• A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or OverweightRecruitingNCT07202884Phase 3
• A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related ComorbiditiesRecruitingNCT06672939Phase 3
• A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)RecruitingNCT06672549Phase 3
• A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy ParticipantsCompletedNCT06704763Phase 1Results posted
• A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or OverweightCompletedNCT06440980Phase 1Results posted
• A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy ParticipantsCompletedNCT06370728Phase 1Results posted
• A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With MetforminCompletedNCT06192108Phase 3Results posted
• A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese ParticipantsCompletedNCT06186622Phase 1Results posted
• A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 InhibitorCompletedNCT06109311Phase 3Results posted
• A Phase I Study of LY3502970 in Healthy ParticipantsCompletedNCT06085482Phase 1Results posted
• A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With MetforminCompletedNCT06045221Phase 3Results posted
• A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related ComorbiditiesCompletedNCT06023095Phase 1Results posted
• A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 DiabetesCompletedNCT06010004Phase 3Results posted
• A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise AloneCompletedNCT05971940Phase 3Results posted
• A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment.CompletedNCT05936138Phase 1Results posted
• A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity DiseaseCompletedNCT05931380Phase 3Results posted
• A Study of LY3502970 in Participants With Impaired and Normal Liver FunctionCompletedNCT05882032Phase 1Results posted
• A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 DiabetesCompletedNCT05872620Phase 3Results posted
• A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesActive, not recruitingNCT05869903Phase 3Results posted
• A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese ParticipantsCompletedNCT05841238Phase 1Results posted
• A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy ParticipantsCompletedNCT05573230Phase 1Results posted
• A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy ParticipantsCompletedNCT05469126Phase 1Results posted
• A Study of Two Different Formulations of LY3502970 in Healthy ParticipantsCompletedNCT05341089Phase 1Results posted
• A Study of LY3502970 in Healthy Overweight and Obese ParticipantsCompletedNCT05313802Phase 1Results posted
• A Multiple-Dose Study of LY3502970 in Healthy ParticipantsCompletedNCT05110794Phase 1Results posted
• A Study of LY3502970 in Japanese Participants With Type 2 Diabetes MellitusCompletedNCT05086445Phase 1Results posted
• A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related ComorbiditiesCompletedNCT05051579Phase 2Results posted
• A Multiple Dose Study of LY3502970 in Healthy ParticipantsCompletedNCT05051566Phase 1Results posted
• A Study of LY3502970 in Participants With Type 2 Diabetes MellitusCompletedNCT05048719Phase 2Results posted
• A Study of LY3502970 in Healthy Male ParticipantsCompletedNCT04680767Phase 1Results posted
• A Study of LY3502970 in Participants With Type 2 DiabetesCompletedNCT04426474Phase 1Results posted
• A Study of LY3502970 in Healthy ParticipantsCompletedNCT03929744Phase 1Results posted
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeActive, not recruitingNCT07153471Phase 3
• A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesActive, not recruitingNCT06993792Phase 3
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 DiabetesActive, not recruitingNCT06972472Phase 3
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related ComorbidityActive, not recruitingNCT06972459Phase 3
• A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2Active, not recruitingNCT06952530Phase 3
• A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1Active, not recruitingNCT06948435Phase 3
• A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)Active, not recruitingNCT06948422Phase 3
• A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or OverweightCompletedNCT06824051Phase 1
• A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy ParticipantsCompletedNCT06692348Phase 1
• A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightCompletedNCT06649045Phase 3
• A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)CompletedNCT06584916Phase 3
• A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskCompletedNCT05803421Phase 3

← Orforglipron overview